Head and neck squamous cell carcinoma (HNSCC) is an extremely aggressive cancer with a poor prognosis and low patient survival. Because chemotherapy for advanced HNSCC is often ineffective, discovering new therapeutic targets that are important for HNSCC development and progression and elucidating their molecular mechanisms are required. In the present study, we describe the role of DRAK1 (death-associated protein kinase-related apoptosis-inducing kinase 1) as a novel negative regulator of the transforming growth factor-β (TGF-β) tumor suppressor signaling pathway for the first time in human HNSCC cells. DRAK1 was significantly overexpressed in primary human HNSCCs and in HNSCC cell lines. Through gain-and loss-of-function experiments, we demonstrated that the DRAK1 expression level regulated TGF-β1-induced transcriptional activity and expression of the tumor suppressor gene p21 Waf1/Cip1 . DRAK1 depletion enhanced TGF-β1-induced growth inhibition in vitro and suppressed tumorigenicity in xenograft models in vivo. Mechanistically, DRAK1 was predominantly localized in the cytoplasm and bound to Smad3, thereby interrupting Smad3/Smad4 complex formation, which is the core process for the induction of tumor suppressor genes by TGF-β1. Thus, our findings suggest that cytoplasmic DRAK1 increases tumorigenic potential through inhibition of TGF-β1-mediated tumor suppressor activity in HNSCC cells and may be a potential therapeutic target for HNSCCs.
INTRODUCTION
Head and neck cancer is one of the most common types of human cancer worldwide and is extremely aggressive. More than 90% of head and neck cancers are squamous cell carcinomas (HNSCCs) originating from the mucosal epithelium. The development of HNSCC is strongly associated with environmental and lifestyle risk factors, including tobacco use, alcohol consumption, ultraviolet light and oncogenic human papillomavirus infections. [1] [2] [3] Earlystage HNSCC is easily curable through surgery, radiation therapy and chemoradiation, whereas patients with advanced HNSCCs at late stages frequently present high mortality rates with little opportunity for receiving effective treatment. 4, 5 Because chemotherapy for advanced HNSCCs is often ineffective, discovering new therapeutic targets that are important for HNSCC development and progression and elucidating their molecular mechanisms are required.
Transforming growth factor-β1 (TGF-β1) has a pivotal role in maintaining epithelial homeostasis, including proliferation, differentiation, migration and apoptosis. 6, 7 Altered responses to TGF-β1 are particularly associated with epithelial cancers. In normal epithelial cells and during the early stages of tumorigenesis, TGF-β1 predominantly functions as a tumor suppressor that inhibits cell growth by inducing tumor suppressor genes, such as p15 Ink4b and p21 Waf1/Cip1 . However, epithelial cancer cells at the late stages of tumor development tend to become resistant to the growth inhibitory effects of TGF-β1. [8] [9] [10] [11] Most advanced HNSCCs have functionally inactivated TGF-β1 tumor-suppressive activity due to the loss of type II TGF-β receptor (TGFBR2), Smad2, and Smad4 because of chromosome deletion or mutation. [12] [13] [14] Although advanced HNSCCs have lost components of the TGF-β signaling pathway, resistance to the tumor-suppressive effects of TGF-β1 in other epithelial cancers is frequently caused by elevated expression levels of negative regulators (Smad7, Smurfs, TMEPAI and CBL) of the TGF-β signaling pathway. [15] [16] [17] [18] Therefore, discovering a novel negative regulator of the TGF-β signaling pathway is important for investigating human HNSCC resistance to TGF-β1 tumor suppressor activity. DRAK1 (death-associated protein kinase-related apoptosisinducing protein kinase 1), which is also called STK17A, is a serine/threonine protein kinase that belongs to the deathassociated protein kinase (DAPK) family and that is identified as a pro-apoptotic protein kinase. 19, 20 Among the DAPK family members, DRAK1 has not been well characterized, and its role in regulating apoptosis remains controversial. Overexpression of DRAK1 in NIH3T3 cells induces morphological changes similar to apoptosis, suggesting that DRAK1 may exert pro-death activity. 19 Moreover, DRAK1 is a direct target gene of p53 and enhances cisplatin-mediated toxicity by regulating reactive oxygen species (ROS) in testicular cancer cells. 21 However, Mao et al. 22 recently demonstrated that DRAK1 was overexpressed in glioblastoma, where it was associated with tumor grade and patient survival, and promoted cell proliferation, migration, invasion and resistance to genotoxic agents.
We previously reported that DRAK2 inhibited TGF-β1 tumor suppressor activity by participating in the negative feedback route of TGF-β signaling by interacting with the type I TGF-β receptor. 23 However, the biological role of DRAK1 in relation to the TGF-β signaling pathway has not yet been investigated. In the present study, we demonstrate that DRAK1 suppresses TGF-β signaling by directly binding to Smad3, which is a key component of TGF-β signaling, thereby preventing Smad3 from forming a complex with Smad4. DRAK1 also inhibits the nuclear translocation of the Smad3 protein upon TGF-β stimulation. Interestingly, DRAK1 is overexpressed in primary human HNSCC samples and in HNSCC cell lines and is predominantly localized in the cytoplasm, indicating that cytoplasmic DRAK1 may have oncogenic activity by inhibiting the tumor-suppressive activity of TGF-β signaling.
RESULTS

DRAK1 is highly expressed in HNSCC cells.
Using the Oncomine database (https://www.oncomine.org), we examined whether DRAK1 mRNA and protein expression was dysregulated in human epithelial cancers. An analysis of public microarray data sets revealed relatively higher DRAK1 mRNA expression levels in HNSCCs compared with other epithelial cancers. A heatmap was generated to visualize DRAK1 mRNA expression levels in three different public HNSCC microarray data sets (GSE9844, GSE6791, and GSE25099; Figure 1a ). [24] [25] [26] Interestingly, DRAK1 was significantly overexpressed in HNSCC patients compared with that in normal controls (Figure 1b ). To investigate DRAK1 protein expression in normal and HNSCC tissues, we performed immunohistochemistry using a specific anti-DRAK1 antibody. The expression of DRAK1 was highly elevated in the tumor compartments of HNSCC patient tissues compared with those in non-neoplastic regions (Figure 1c ). We also investigated the expression levels of DRAK1 mRNA and protein by reverse transcriptase PCR and immunoblotting, respectively, in six human HNSCC cell lines. Most of the HNSCC cell lines displayed high expression levels of DRAK1 mRNA and protein ( Figure 1d ). Taken together, these results suggest that DRAK1 is overexpressed in HNSCC cells.
The expression level of DRAK1 regulates the TGF-β signaling pathway in HNSCC cells Recently, we reported a novel role of DRAK2 as a negative regulator of TGF-β signaling, which exerted oncogenic effects by suppressing the TGF-β signaling pathway. 23 Considering that DRAK1 displayed high homology with DRAK2 among the DAPK family members, we hypothesized that DRAK1 might regulate TGF-β signaling similar to DRAK2. To examine whether DRAK1 expression regulated TGF-β signaling in HNSCC cells, we performed gain-and loss-of-function experiments by generating retrovirus-or lentivirus-transduced cell lines stably overexpressing DRAK1 protein or DRAK1-specific short hairpin RNA (shRNA). Because PCI-13 and SNU-1041 did not express the Smad4 gene, which is a key mediator in TGF-β signaling, we selected the PCI-1 and PCI-50 cell lines among the tested HNSCC cell lines (Supplementary Figure S1 ). The PCI-1 cell line exhibited relatively high levels of DRAK1 expression among the HNSCC cell lines tested. To determine whether the loss of DRAK1 gene expression regulated TGF-β signaling, we generated DRAK1-knockdown stable PCI-1 cell lines using the shRNA lentiviral system (Supplementary Figure S2a ). We also generated retrovirustransduced stable PCI-50 cell lines stably overexpressing the DRAK1 protein because PCI-50 cell lines expressed relatively low levels of the DRAK1 protein (Supplementary Figure S2b ). To investigate whether DRAK1 influenced TGF-β1-induced transcriptional activation, we tested the effect of DRAK1 on TGF-β signaling using the TGF-β1-responsive CAGA 12 -Luc reporter. DRAK1 overexpression significantly decreased TGF-β1-induced transcriptional activity (Figure 2a ), whereas DRAK1 knockdown enhanced its activity (Figure 2e ). TGF-β1-induced cell growth inhibition is mediated by the induction of cell cycle arrest-related genes, such as p15 Ink4b and p21 Waf1/Cip1 . Because p15 Ink4b is frequently inactivated by a homozygous deletion in HNSCC cells, 27 we examined the mRNA and protein levels of the TGF-β1-induced tumor suppressor gene p21 Waf1/Cip1 by quantitative reverse transcriptase PCR and immunoblotting, respectively. Overexpression of DRAK1 reduced the p21 Waf1/Cip1 expression at mRNA gene and protein levels (Figures 2b and c), whereas endogenous DRAK1 depletion dramatically enhanced p21 Waf1/Cip1 expression ( Figures  2f and g) . Because the promoter of the p21 Waf1/Cip1 gene includes TGF-β1-responsive elements, which are Smad2/3 binding sites, we also tested the effect of DRAK1 on the TGF-β1-induced promoter activity of p21 Waf1/Cip1 . Elevated DRAK1 expression decreased p21 Waf1/Cip1 promoter activity on TGF-β1 treatment (Figure 2d ), whereas DRAK1 knockdown displayed the opposite result ( Figure 2h ). These results suggest that DRAK1 may induce the inactivation of the growth inhibitory effect of TGF-β1 by inhibiting TGF-β1-induced transcriptional activation of the tumor suppressor gene p21 Waf1/Cip1 in HNSCC cells.
Depletion of endogenous DRAK1 suppresses tumor formation in HNSCC cells
Because DRAK1 knockdown dramatically enhanced the TGF-β1induced expression of the p21 Waf1/Cip1 gene, we investigated whether DRAK1 knockdown influenced TGF-β1-mediated growth inhibition in HNSCC cells. Compared with control cells, DRAK1 knockdown enhanced the ability of TGF-β1 to inhibit proliferation ( Figure 3a ). Moreover, DRAK1 knockdown reduced the growth of control cells even in the absence of TGF-β1 treatment. To further test whether DRAK1 knockdown affected the clonogenic potential of HNSCC cells, we performed a foci formation assay. TGF-β1 treatment in DRAK1-knockdown PCI-1 cells significantly decreased foci formation compared with control cells (Figure 3b ). Next, to confirm the effects of DRAK1 depletion on tumorigenesis in vivo, we subcutaneously injected DRAK1-knockdown PCI-1 cells into the flanks of severe combined immunodeficiency mice. We observed that DRAK1 knockdown in PCI-1 cells significantly reduced tumor formation, suggesting that DRAK1 is required to reinforce tumorigenicity in vivo (Figures 3c and d ).
Overexpression of DRAK1 blocks complex formation between Smad3 and Smad4 through interaction with Smad3
Because DRAK2 inhibited the TGF-β1-induced phosphorylation of Smad3 through interaction with the type I TGF-β receptor, 23 we examined whether DRAK1 also suppressed TGF-β signaling by inhibiting Smad3 phosphorylation. Surprisingly, neither the overexpression nor knockdown of DRAK1 affected TGF-β1-induced Smad3 phosphorylation, indicating that DRAK1 might inhibit TGFβ signaling downstream of the type I TGF-β receptor (Figures 4a  and b ). To study the mechanism behind the suppression of the TGF-β signal by DRAK1, we first tested the interaction between Smad2, Smad3 or Smad4 and the human DRAK1 protein in 293T cells transiently transfected with plasmids encoding Flagtagged Smad2, Flag-tagged Smad3, or Flag-tagged Smad4 with GST-fused DRAK1. Interestingly, DRAK1 interacted strongly with Smad3 and weakly with Smad2, whereas DRAK1 did not bind to Smad4 (Figure 4c ). In the case of DRAK2, Smad2/3/4 proteins did not interact with GST-fused DRAK2. To further explain the physiological significance of the interaction between DRAK1 and Smad3, we investigated the interaction between endogenous Smad3 and DRAK1. As expected, endogenous Smad3 interacted with endogenous DRAK1 even in the absence of TGF-β treatment (Figure 4d ). TGF-β1-induced transcriptional regulation is controlled by the nuclear translocation of Smad3. Because neither the knockdown nor the exogenous expression of DRAK1 had an effect on Smad2/3 phosphorylation, we hypothesized that DRAK1 might suppress the cellular responses of TGF-β1 by blocking the translocation of Smad3 into the nucleus. Therefore, to determine whether DRAK1 influences the subcellular localization of Smad3, we performed confocal microscopic analysis using anti-Myc and anti-Smad3 antibodies in PCI-50 cells stably overexpressing Myctagged DRAK1 protein. As shown in Figure 4e , TGF-β1 induced the translocation of Smad3 from the cytoplasm to the nucleus in control cells, whereas DRAK1 overexpression significantly blocked TGF-β1-induced translocation into the nucleus. Interestingly, DRAK1 was predominantly localized in the cytoplasm in DRAK1overexpressing PCI-50 cells (Figure 4e ). A previous report revealed that DRAKs are exclusively localized in the nucleus or localized in both the cytoplasm and the nucleus, depending on cell type. 19 Therefore, we investigated whether subcellular localization of DRAK1 was dependent on the cell context. Subcellular fractionation experiments revealed that DRAK1 was exclusively localized to the cytoplasm in the PCI-1 and PCI-50 HNSCC cell lines, whereas DRAK1 was localized to both the cytoplasm and the nucleus in the HEK293 (human embryonic kidney cells) and HeLa (human cervical cancer cells) cell lines (Supplementary Figure S3 ). To elucidate underlying the mechanism by which DRAK1 inhibits TGF-β/Smads signaling via its association with Smad3, we examined the effect of DRAK1 on Smad3/Smad4 complex formation, which is critical for the transduction of TGF-β signal. The immunoprecipitation assay demonstrated that ectopically expressing DRAK1 interrupted Smad3/4 complex formation (Figure 4f ), whereas DRAK1 depletion enhanced the TGF-β1induced endogenous complex formation of Smad3/4 (Supplementary Figure S4) . Consistent with the above observation, the subcellular fractionation analysis revealed that DRAK1 overexpressed in the cytoplasm decreased the TGF-β1-induced translocation of Smad3 and Smad4 into the nucleus (Figure 4g ). Taken together, these data indicate that the overexpression of cytoplasmic DRAK1 in HNSCC cells inhibits TGF-β signaling by interrupting Smad3/4 complex formation in the cytoplasm, thereby attenuating the tumor-suppressive activity of TGF-β1. DRAK1 binds to the MH2 domain of Smad3 through its kinase domain Next we attempted to determine which region of Smad3 was responsible for its interaction with DRAK1. We used a series of deletion mutants of Flag-tagged Smad3 and GST-fused DRAK1 and performed a GST pull-down assay. As shown in Figure 5a , DRAK1 specifically bound to the MH2 domain of Smad3, which is known to interact with Smad4, suggesting that DRAK1 and Smad4 might compete for the interaction with Smad3. We also found that residues 1-193 of DRAK1, including the N terminus and a portion of the kinase domain, failed to interact with Smad3, whereas Smad3 bound to a DRAK1 kinase domain mutant containing Figure 5b ). To further determine the minimal binding motifs of DRAK1, we generated various deletion constructs of the DRAK1 kinase domain. Smad3 was associated with a DRAK1 kinase domain deletion mutant containing amino acids 214-256, suggesting that residues 214-256 in the DRAK1 kinase domain are critical for the interaction with Smad3 (Figure 5c ). DRAK1 displays the highest homology to the DRAK2 kinase domain (59.7%) among the kinase domains of other DAPK family members. 19 Because DRAK2 did not interact with Smad3, as shown in Figure 4c , we hypothesized that Smad3 might bind to residues 214-256 of DRAK1, which did not display any significant homology with the DRAK2 kinase domain (Supplementary Figure  S5) . Therefore, we compared residues 214-256 of DRAK1 with the corresponding domain of DRAK2 (Figure 5d ). To further define the Smad3-binding sequences in residues 214-256 of DRAK1, we generated double amino-acid substitution mutants (K215A and E218A) of DRAK1. DRAK1 K215A/E218A dramatically reduced the DRAK1 interaction with Smad3 (Figure 5e ). Next to confirm the significance of the Smad3-binding motif of DRAK1 in TGF-β signaling, we monitored TGF-β1-induced transcriptional activation and the interaction between Smad3 and Smad4. DRAK1-mediated inhibition of the TGF-β1-induced transcriptional activity of CAGA 12 -Luc was abolished by DRAK1 K215A/E218A (Figure 5f ). In addition, substitution of amino acids K215A/E218A in DRAK1 markedly reduced the ability of DRAK1 to interrupt Smad3/4 complex formation (Figure 5g ). These results indicate that the binding of Smad3 to residues 214-256 of DRAK1 is required for the DRAK1-mediated inhibition of TGF-β signaling.
Kinase inactivation of DRAK1 enhances TGF-β signaling DRAK1 is a serine/threonine kinase and can be autophosphorylated. 19 To confirm whether the kinase activity of DRAK1 is required to inhibit TGF-β signaling, we generated a kinase-inactive mutant of DRAK1 (DRAK1 K90A) by replacing Lys 90, which is an ATP-binding site in the kinase domain, with Ala. DRAK1 wild type interacted with Smad3, whereas the kinaseinactive mutant form (K90A) of DRAK1 significantly decreased its interaction with Smad3 ( Figure 6a ). Furthermore, the ability of DRAK1 to suppress TGF-β1-induced transcriptional reporter activity and Smad3 nuclear translocation was markedly attenuated by the functional loss of DRAK1 (Figures 6b and c) . To examine whether the kinase activity of DRAK1 influenced the interaction between Smad3 and Smad4, we performed an immunoprecipitation assay. Unlike DRAK1 wild type, DRAK1 K90A did not interrupt the interaction between Smad3 and Smad4 suggesting that the kinase activity of DRAK1 is essential for inhibiting TGF-β signaling by interrupting Smad3/4 complex formation. We also investigated whether Smad3 is phosphorylated by DRAK1. Immunoprecipitation assay showed that DRAK1 did not phosphorylate Smad3 (Supplementary Figure 6) .
DISCUSSION
It has been known that resistance to TGF-β1-mediated growth inhibitory effects in advanced HNSCCs is caused by the deletion or downregulation of key components of TGF-β signaling. [12] [13] [14] 28 However, the resistance of advanced HNSCCs, which harbor intact components of the TGF-β signaling pathway, to TGF-β tumor suppressor activity via negative regulators of TGF-β is poorly understood. Our results suggest for the first time that cytoplasmic DRAK1 overexpressed in HNSCC cells renders resistance to TGF-β1 tumor-suppressive effects by interrupting Smad3/4 complex formation. DRAK1 specifically binds to Smad3, and this interaction blocks the translocation of Smad3/4 complex into the nucleus, thereby promoting the tumorigenesis of HNSCC cells by suppressing the TGF-β1-induced expression of the tumor suppressor gene p21 Waf1/Cip1 . Our findings provide unique evidence that DRAK1 overexpression can contribute to HNSCC cell resistance to TGF-β1mediated growth inhibitory effects through direct interaction with Smad3. The DAPK family is associated with several types of stimulusinduced apoptotic cell death. [29] [30] [31] For example, DAPK1 expression is induced by TGF-β1 through the Smad2/3-dependent signaling pathway, resulting in increased mitochondrial pro-apoptotic events in hepatocellular carcinoma cells. 31 Furthermore, ectopic expression of DRAK1 and DRAK2 has been shown to induce apoptotic cell death in several epithelial cancer cells. 19, 21 However, the role of DRAK1 in regulating apoptosis remains controversial. DRAK1 overexpression induces morphological changes similar to apoptosis in NIH3T3 or HeLa cells, indicating a possible role for DRAK1 in apoptotic signaling. 19 Moreover, DRAK1 is upregulated by cisplatin, which is a DNA-damaging agent, in a p53-dependent manner, and depletion of endogenous DRAK1 confers resistance to the cisplatin-induced inhibition of cell growth in testicular cancer cells. 21 In contrast, DRAK1 overexpression in glioblastoma, where this gene is associated with tumor grade and survival in patients, promoted cell proliferation and resistance to genotoxic stress. 22 In this study, we demonstrated that DRAK1 is overexpressed in HNSCC cells and contributes to the resistance to TGF-β1 tumor-suppressive effects.
We have recently demonstrated that DRAK2 is a negative regulator of TGF-β signaling, inhibiting Smad2/3 phosphorylation through its interaction with the type I TGF-β receptor. 23 Because DRAK1 and DRAK2 share a similar kinase domain among DAPK family members, we hypothesized that DRAK1 might also regulate TGF-β1-induced Smad2/3 phosphorylation. Interestingly, DRAK1 did not suppress TGF-β1-induced Smad2/3 phosphorylation, suggesting that DRAK1 acted downstream of the receptormediated TGF-β signaling pathway. Instead, we found that DRAK1 Based on the work presented in the present study, we have demonstrated that residues 213-218 of DRAK1, which are not well-conserved in the DRAK2 kinase domain, are critical residues for Smad3 binding. DRAK1 is a serine/threonine kinase. We also found that the kinase-inactive mutant form of DRAK1 was unable to block TGF-β signaling and form a complex with Smad3. These results indicate that DRAK1 kinase activation results in the inhibition of the TGF-β downstream signaling pathway through its interaction with the MH2 domain of Smad3, thereby contributing to the downregulation of Smad3/4-dependent TGF-β signaling. DRAK1 is predominantly localized in the nucleus of various cancer cells. 19 Surprisingly, unlike other epithelial cells, such as HEK293 and HeLa cells, in which DRAK1 is localized in both the cytoplasm and the nucleus, DRAK1 was predominantly localized in the cytoplasm in HNSCC cells, as demonstrated by subcellular fractionation and confocal imaging. Immunohistochemical staining experiments further supported this observation by revealing the localization of DRAK1 in the cytoplasmic compartment of HNSCC tissue samples. Therefore, cytoplasmic DRAK1 overexpressed in HNSCC cells may specifically suppress TGF-β signaling by interrupting Smad3/4 complex formation in the cytoplasm. Further studies will be required to better understand the role of cytoplasmic DRAK1 in many cancer cells.
Inactivation of the TGF-β signaling pathway in HNSCC progression has been shown to occur through the loss of the TGFBR2, Smad2 and Smad4 because of chromosome 18q deletion or mutation. [12] [13] [14] Previous studies have demonstrated that Smad4knockout mice generate spontaneous HNSCCs with increased genomic instability and inflammation. 14 Furthermore, although the mechanisms of the loss of Smad2 in HNSCCs have not yet been evaluated, Smad2 may be inactivated by a loss of heterozygosity close to the Smad4 gene locus on chromosome 18q21. 32 However, the underlying mechanism of the resistance to the growth inhibitory effect of TGF-β1 by altered expression of negative regulators in HNSCC cells is not understood. The fact that the DRAK1 functions as a novel negative regulator of TGF-β signaling suggests that enhanced DRAK1 expression may lead to the suppression of the TGF-β signaling pathway in HNSCC cells. Indeed, our studies demonstrated that the elevated expression of DRAK1 contributed to the tumorigenicity of human HNSCC cells. DRAK1 knockdown markedly enhanced the TGF-β1-induced inhibition of cell growth and suppressed tumorigenic capacity in vivo.
In conclusion, we have demonstrated that cytoplasmic DRAK1 overexpressed in HNSCC cells attenuated TGF-β tumor-suppressive activity by inhibiting Smad3/4 complex formation through its direct interaction with Smad3. Considering the evidence that aberrant expression of negative regulators related to TGF-β signaling is strongly linked to tumorigenicity in human HNSCC cells, DRAK1 may be a potential therapeutic target for HNSCCs.
MATERIALS AND METHODS
Reagents and antibodies TGF-β1 was purchased from R&D Systems (Minneapolis, MN, USA). Protein A/G beads were purchased from Santa Cruz Technology (Santa Cruz, CA, USA). Antibodies were obtained from Santa Cruz Technology (anti-Myc, anti-HA, anti-GFP, anti-LaminB, anti-GST, anti-Smad3, anti-Smad4 and anti-p21), Cell Signaling Technology (Danvers, MA, USA) (anti-pSmad3 Ser423/425, anti-Smad3 and anti-DRAK2 33D7), Abcam (Cambridge, MA, USA) (anti-Smad3), Imgenex Corp. (San Diego, CA, USA) (anti-DRAK1 CT) and Sigma-Aldrich (St Louis, MO, USA) (anti-β-actin, anti-α-tubulin and anti-Flag M2).
Cell lines and culture conditions
The cell lines used in our study were PCI-1, PCI-13, PCI-50, SNU-1041, SNU-1066 and SNU-1076, which were all derived from HNSCCs. All of the cell lines were obtained from the Department of Otorhinolaryngology (Seoul National University College of Medicine, Seoul, South Korea) and were maintained in Dulbecco's modified Eagle's medium (WelGENE, Seoul, South Korea) containing 10% fetal bovine serum and 1% penicillin/streptomycin.
Transcription reporter assay
Transfections were performed with polyethylenimine or with FuGENE 6 HD (Roche, Indianapolis, IN, USA) according to the manufacturer's instructions. Cells were seeded in triplicate in 24-well plates at a density of 2 × 10 4 cells per well and were transiently transfected with CAGA-Luc and p21 promoter-Luc. Then, 24 h post transfection, cells were treated with 5 ng per ml TGF-β1 for 16 h. For the luciferase analysis, cells were harvested with luciferase cell culture lysis reagent (Promega, Madison, WI, USA). Luciferase activities were measured using the luciferase assay system (Promega) according to the manufacturer's protocol. All of the values were normalized with β-galactosidase activities.
Viral production and cell infections
DRAK1 shRNA lentiviral vectors (Sigma-Aldrich) were used for the DRAK1 knockdown. For DRAK1 shRNA lentivirus production, 293T cells were transfected with pLKO-shDRAK1 or with scrambled control pLKO-pGL2, together with the packaging plasmids encoding Δ8.9 and VSV-G. Myctagged DRAK1 stably expressing cells were generated by retrovirus infection. For retrovirus production, GP2-293 cells were transfected with LPCX-Myc-DRAK1 or with LPCX control with VSV-G. Viral supernatants were collected 36 and 48 h post transfection and filtered through a 0.45-μm filter. Cells were seeded at 1 × 10 5 cells/well into six-well plates. Cells were infected with viral particles and with polybrene (8 μg per ml). After the infection, the virus-containing medium was replaced with normal medium, and then all of the cells were selected by puromycin (2 μg per ml).
Immunoprecipitation and western blot analysis
Cells were washed twice in cold PBS and lysed in IP buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 2 mM EDTA and 10% glycerol) plus phosphatase and protease inhibitors (Roche). Whole-cell extracts were incubated with the appropriate primary antibodies overnight at 4°C. Antibody-bound proteins were precipitated with protein A/G beads according to the manufacturer's protocol. The beads were washed three times with lysis buffer and then eluted in 2X SDS sample loading buffer. Eluted proteins were separated by SDS-polyacrylamide gel electrophoresis, transferred to PVDF membranes (Millipore, Billerica, MA, USA), and detected using appropriate primary antibodies coupled with a horseradish peroxidase-conjugated secondary antibody by chemiluminescence (GE Healthcare Life Sciences, Piscataway, NJ, USA).
Immunofluorescence
Cells seeded on chamber slides were fixed in ice-cold acetone for 5 min on ice. Cells were blocked with 5% bovine serum albumin for 1 h and incubated with anti-Myc or anti-Smad3 antibodies overnight at 4°C. Antibody-bound cells were detected by Alexa Fluor 488 or 594-conjugated secondary antibody (Invitrogen, Carlsbad, CA, USA). Immunofluorescence images were obtained using a Zeiss LSM META 510 confocal microscope.
Reverse transcription and quantitative PCR
Total RNA was isolated from cells using TRIzol reagent (Invitrogen) according to the manufacturer's protocol. Reverse transcription was performed with 1 μg of pure RNA using SuperScript II reverse transcriptase (Invitrogen). The synthesized cDNA was amplified by PCR using specific primers. PCR products were visualized by electrophoresis on agarose gels with RedSafe (iNtRON) staining and analyzed using an ImageQuant LAS 4000 image analyzer (GE Healthcare Life Sciences). Quantitative PCR was performed using Assay-on-Demand kits and a Viia7 real-time PCR device (Applied Biosystems, Carlsbad, CA, USA). 18S rRNA served as the housekeeping gene.
Focus-forming assay
Two hundred cells were seeded per well in six-well plates. After incubation for 10 days, the colonies were rinsed with PBS and stained with 2% methylene blue. All of the experiments were performed in triplicate.
Xenograft assay
PCI-1 cell lines stably expressing control shRNA or DRAK1-specific shRNA (2 × 10 6 ) were subcutaneously injected into the flanks of severe combined immunodeficiency mice (six mice per group). Tumor dimensions were measured once per week. Mice were killed 5 weeks after injection and the tumors were surgically isolated. The tumor volume (V) was calculated using the formula (S × S × L) × 0.5, where S and L were the short and long dimensions, respectively. All of the animals were maintained according to the CHA Hospital Animal Care and Use Committee guidelines under protocol number IACUC110004. Immunohistochemistry HNSCC tissue microarray sections (AccuMax Array) were purchased from ISUABXIS (Seoul, South Korea). For immunohistochemistry, tissue microarray sections were fixed and stained using anti-DRAK1 antibodies. Visualization was performed with amino-ethylcarbazole.
Microarray data analysis
We downloaded expression data from a public database [24] [25] [26] and extracted the expression values of the DRAK1 gene, as described previously. 33 The NeatMap package for R (http://www.r-project.org) was used to draw a heatmap. The Student's t-test was performed to compare the mean expression across the experimental conditions.
